← FDA DRUG APPROVALS

FDA ANDA · ANDA208813

TOREMIFENE CITRATE

Sponsor: RISING

APPLICATION
ANDA208813
TYPE
ANDA
ORIGINAL APPROVAL
2018-12-04
LATEST ACTION
2026-01-14
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

TOREMIFENE CITRATEPrescription
TOREMIFENE CITRATE EQ 60MG BASE · TABLET · ORAL

Approval history

2026-01-14Labeling · Supplement 4 · standardAP
2018-12-04UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →